Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
EMXC vs XBI: how they differ
EMXC and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
iShares MSCI Emerging Markets ex China ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, EMXC and XBI hold 0% of their money in the same securities at the same weight.
| Only in EMXC | Only in XBI |
|---|---|
| Taiwan Semiconductor Manufacturing Compa 17.97% | Apogee Therapeutics Inc 1.49% |
| SK hynix Inc. 8.37% | Moderna Inc 1.41% |
| MediaTek Inc. 2.04% | Twist Bioscience Corp 1.41% |
| DELTA ELECTRONICS, INC. 1.47% | Oruka Therapeutics Inc 1.38% |
| HON HAI PRECISION INDUSTRY CO., LTD. 1.13% | Kymera Therapeutics Inc 1.36% |
| Samsung Electronics Co., Ltd. 1.07% | Viking Therapeutics Inc 1.31% |
| HDFC BANK LIMITED 0.88% | Praxis Precision Medicines Inc 1.29% |
| RELIANCE INDUSTRIES LIMITED 0.83% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| EMXC iShares MSCI Emerging Markets ex China ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | MSCI Emerging Markets ex China | SPDR S&P Biotech |
| Total return, 1 year | +55.5% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +38.0 pts | +46.5 pts |
| Expense ratio | 0.25% | 0.35% |
| Already in the S&P 500 | 0.0% | 8.5% |
| Holdings | 662 | 150 |
EMXC in plain words
EMXC is an index equity fund tracking the MSCI Emerging Markets ex China. Over the year to Sep 11, 2026 it returned +55.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.25% a year. By its holdings filed for May 31, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 662 positions, with the top ten at 44.3%. It sat 5.5% below its high of Jun 22, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, EMXC or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, EMXC returned +55.5% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, EMXC or XBI?
- EMXC charges 0.25% a year and XBI charges 0.35%, so EMXC is cheaper. Fees come from each fund's prospectus.
- How much do EMXC and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of EMXC and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, EMXC against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/EMXC-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources